<DOC>
	<DOCNO>NCT02185560</DOCNO>
	<brief_summary>This non-interventional , multi center post-authorization safety study include patient diagnose Unresectable Differentiated Thyroid Carcinoma ( DTC ) treat Sorafenib within certain period . The investigator make choice treatment ( NEXAVAR ) accord Japanese Package Insert prior enrol patient study . The enrollment period 9 month . The observation period patient start therapy NEXAVAR initiate . Patients follow 9 month longer possible ( e.g . lose follow-up ) ; consider standard observation period . Those patient , total 24 month follow possible , information effectiveness include treatment duration survival status patient keratoacanthoma and/or squamous cell cancer development collect .</brief_summary>
	<brief_title>Prospective , Non-interventional , Post-authorization Safety Study That Includes All Patients Diagnosed Unresectable Differentiated Thyroid Carcinoma Treated With Sorafenib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients start NEXAVAR treatment radioactive iodinerefractory unresectable Differentiated Thyroid Carcinoma ( DTC ) Patients already receive NEXAVAR treatment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Sorafenib</keyword>
	<keyword>Differentiated Thyroid Carcinoma ,</keyword>
	<keyword>Japan</keyword>
	<keyword>Post Marketing Surveillance</keyword>
	<keyword>Drug Use Investigation</keyword>
</DOC>